VRTX•benzinga•
Vertex Pharmaceuticals Announced Results From Its Phase 2 Study Of Suzetrigine For Painful Lumbosacral Radiculopathy, The Study Met Its Primary Endpoint With Statistically Significant And Clinically Meaningful Reduction In Pain On The Numeric Pain Rating
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on December 19, 2024 by benzinga